Building on earlier research and development efforts, a key milestone was reached in 1994 when one of our early medical device models received FDA clearance under interferential current therapy. These systems featured an Ultra High Digital Frequency Generator (UHdfg) with FM modulation and utilized spread-spectrum frequency hopping (FHSS) technology—an approach rooted in principles of quantum physics. This clearance marked a foundational step toward digitally enhanced, non-linear signal delivery and helped lay the groundwork for our evolution into advanced Electric Cell Signaling systems.

In the early 2000’s, we were granted a U.S. patent for our Sequentially Generated Multi-Parameter Bio-Electric Delivery System Method - an innovation that advanced electrotherapeutics by enabling more precise, layered signaling techniques for targeted therapeutic applications. This breakthrough paved the way for FDA clearance of an updated device model with expanded capabilities, classified under TENS, powered muscle stimulation, and interferential current therapy. The clearance broadened the system’s recognized applications to include not only pain management, but also circulatory support and rehabilitative use. Utilizing spread-spectrum frequency hopping (FHSS) technology along with frequency and amplitude modulation, the system delivered dynamic, varied signal patterns designed for comfortable and effective treatment across a range of clinical indications. Building on this foundation, we refined our signal delivery with influences such as Schumann resonance, Solfeggio frequencies, and Fibonacci-based mathematical principles, shaping harmonic modulation patterns to better align with the body’s natural rhythms. These advancements, combined with enhanced AM/FM layering, improved therapeutic performance while reducing nerve accommodation, and were complemented by new provider resources such as smart card access for personalized treatment programs. This period also saw the introduction of Electric Signal Intonation (ESI), a treatment pattern using a quarter-tone musical scale within select programs. Designed to deliver physiologically resonant frequencies, ESI further enhanced the system’s ability to work in harmony with biological processes.

During this period, we continued building on prior advancements by refining therapeutic programs, enhancing client support systems, and deepening the clinical utility of our technology. We expanded our exploration of frequency-based therapeutics—drawing ongoing inspiration from pioneers in energy medicine—and introduced complementary modalities such as red and infrared light therapy and therapeutic vibration. These additions were selected to work synergistically with the neoGEN® System and the human body, offering additional delivery pathways for frequency-based care. Alongside these developments, we advanced signal sequencing, frequency harmonics, and program architecture, all while continuing to support providers with practical tools and clinical resources.

As demand for the neoGEN® System grew, we expanded our production capabilities between 2019 and 2020 to include in-house manufacturing at our U.S. facility—while continuing to uphold the high standards established through decades of trusted German engineering. This dual-location approach allows us to better meet customer needs by improving turnaround times, streamlining support, and maintaining greater control over quality and inventory—all while reinforcing our long-standing commitment to precision and performance.

In 2021, we expanded our system lineup with the release of two refined models designed to meet specific clinical needs. The neoGEN® PT maintained the core technology of the standard system but was reorganized to better align with physical therapy practices, emphasizing pain relief, neuromuscular reeducation, circulation, and functional rehabilitation. That same year, we reintroduced the neoGEN® Basic - a streamlined, 2-channel unit ideal for single-area treatments and practices seeking a focused, compact solution.

Today, our focus remains on advancing the capabilities of our technology while supporting providers through accessible education, clinical resources, and responsive service. We continue to explore opportunities for future innovation—including expanded system models, home-use concepts, and additional delivery methods that align with our frequency-based approach. As part of this evolution, we are also growing our offering of complementary modalities that work in harmony with the neoGEN® System and the human body. With more to come, our commitment is clear: to stay at the forefront of non-invasive, integrative therapies that empower both providers and patients.